Global Exocrine Pancreatic Insufficiency (EPI) Market Research Report: Forecast (2024-2030)

Market Definition

Treatment primarily given to patients suffering from Exocrine pancreatic insufficiency (EPI) & experiencing symptoms such as difficulties in digesting and absorbing nutrients from food. These treatment techniques often involve enzyme replacement therapy to aid digestion, improve nutrient absorption, and optimize nutritional intake.

Market Insights & Analysis: Global Exocrine Pancreatic Insufficiency (EPI) Market (2024-30):

The Global Exocrine Pancreatic Insufficiency (EPI) Market is estimated to grow at a CAGR of around 7.2% during the forecast period, i.e., 2024-30. The factors contributing to a surge in the demand for therapies are the growing awareness about these updated therapies among healthcare professionals and the growth of the population dealing with pancreatic ailments.

Further, the presence of a large number of overweight and obese individuals worldwide has positively influenced the Exocrine Pancreatic Insufficiency (EPI) Market. For instance, as per the World Health Organization (WHO), in 2022, around 2.5 billion adults were overweight and approximately 890 million people were living with obesity.

The inhabitants with obesity & weight problems have been linked to a lack of endocrine and other pancreatic disorders. Hence, with such a high preponderance of obesity, the risk for an exocrine pancreatic shortage has expanded. It has led consumers to go through a proper diagnosis and treatment, either through nutritional therapy or PERT. As a result, the Global Exocrine Pancreatic Insufficiency (EPI) Market has been recording growth.

Also, individuals & nations across the globe are glimpsing economic growth due to which there has been a swell in healthcare spending. This rise in healthcare expenses worldwide is leading to more additional aid allotment at health centers for providing high-quality diagnosis, treatment, and administration of chronic conditions. Therefore, individuals dealing with these issues are benefiting from healthcare services and treatments quickly, thereby driving market growth.

Global Exocrine Pancreatic Insufficiency Market Driver:

Rising Incidences of Pancreatic Disorders Escalating the Demand – In recent years, there has been a surge in patients suffering from cystic fibrosis and other pancreatic disorders due to genetic predispositions & other lifestyle factors. These health-related concerns result in the shortage of the exocrine leading to digestion issues. Therefore, to eradicate these health issues, customers across the globe are pursuing solutions that help to fulfill the nutritive needs of the body.

Similarly, the individuals are also suffering from pancreatic cancer, which mainly concerns the pancreas of the individual. For instance, according to the Global Cancer Observatory, worldwide in 2022 there were about 511 thousand new cases of pancreatic cancer and by 2045 it will increase to 911 thousand.

Therefore, the inhabitants suffering from these deadly cancers require immediate medical intervention and undergo treatments that offer smooth functioning of the vital body organs. Further, the investigation conducted by several research associations states that the number of individuals suffering from pancreatic cancer would continue to rise. Consequently, this would further accelerate the need for different treatment options available, thereby driving the overall market for Exocrine Pancreatic Insufficiency.  

Global Exocrine Pancreatic Insufficiency Market Opportunity:

Increasing Clinical Trials for Exocrine Pancreatic Insufficiency Therapeutics to Open New Doors for Market Players – Globally, there has been a notable increase in the awareness and diagnosis of exocrine pancreatic insufficiency, largely due to improved diagnostic procedures and greater awareness among healthcare providers about the symptoms and importance of EPI. This increase in diagnosis has fueled the demand for mixed treatment options, which subsequently is increasing clinical trials for exocrine pancreatic insufficiency therapeutics.,

• In 2023, First Wave BioPharma, Inc., announced the initiation of its planned Phase 2 clinical trial of an enhanced enteric micro granules delivery formulation for adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) in the US.

Also, the surging fund allocation to conduct clinical trials & research would enhance the number of treatments and therapies, which subsequently would provide better outcomes compared to existing treatments, thus broadening the potential customer base.

Global Exocrine Pancreatic Insufficiency Market Challenge:

High Cost of Exocrine Pancreatic Insufficiency Therapeutics Impede Market Growth – Exocrine Pancreatic Insufficiency Therapeutics are based on emerging technologies. Therefore, the price of these therapies is relatively higher than traditional therapies. According to the company website, the average cost lies within the range of USD 2,109 to USD 4,840. The more heightened cost of treatment procedures causes apprehension among consumers residing in undeveloped or low economies, where per capita is relatively less.

Further, consumers suffering from insufficiency are required to undergo these therapy frequently. Therefore, the overall cost of treatment becomes more and the consumers with financial restraints opt for the alternatives, slowing down the demand for Exocrine Pancreatic Insufficiency Therapeutics.

Additionally, the lowly developed countries lack the necessary resources, like skilled labor to conduct these therapies. As a result, these therapies are inaccessible for the consumers of undeveloped countries, negatively impacting the market growth.

Global Exocrine Pancreatic Insufficiency Market Trend:

Rising Shift Toward Precision Medicine & Personalized Therapies – Each & Every individual has a different body weight & vitals, therefore conventional therapies sometimes fail to eradicate the illness properly and might show positive outcomes after a long time. Therefore, to get relief from the pain & symptoms caused by pancreatic insufficiency, individuals are increasingly looking for customized therapeutic solutions. These advanced therapeutic approaches help healthcare professionals to identify the root cause associated with exocrine pancreatic insufficiency, allowing the healthcare practitioners to prescribe the medications & therapies based on the patient’s need. This consequently results in faster & positive outcomes.

Furthermore, patients suffering from other chronic illnesses also experience exocrine pancreatic insufficiency due to the disease's impact on the pancreas. Therefore, there is a rising focus on healthcare professionals to provide personalized medicine to patients who might suffer from insufficiency afterward. These tailored approaches enhance treatment consequences, minimize adverse effects, and improve patient satisfaction, thereby, enlarging the Global Exocrine Pancreatic Insufficiency Market size.  

Global Exocrine Pancreatic Insufficiency Market (2024-30): Segmentation Analysis

The Global Exocrine Pancreatic Insufficiency Market study by MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2024–2030 at the regional level. In accordance to the analysis, the market has been further classified as:

Based on the Treatment Method:

• Pancreatic exocrine replacement therapies (PERT)
• Nutritional Therapy

Among them, Pancreatic exocrine replacement therapies (PERT) hold a dominant market share in the Global Exocrine Pancreatic Insufficiency Market. These therapies follow a targeted approach that helps in addressing the underlying reason for the exocrine deficit. This consequently improves the patient's health, thereby, garnering the interest of healthcare providers & patients, potentially driving increased adoption and market growth.

Additionally, improved symptom management and better digestion facilitated by PERT have led to reduced hospitalizations, improved nutritional status, and overall better health outcomes. These have contributed to the growing priority for Pancreatic Exocrine Replacement Therapies (PERT). As a result, the Pancreatic Exocrine Replacement Therapies (PERT) segment has witnessed significant growth.

Based on the Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Of them all, Online Pharmacies hold a prominent market share in the Global Exocrine Pancreatic Insufficiency Market. In recent years, the governing authorities have increasingly worked on modernizing their digital infrastructure. As a result, several nations have recorded a surge in internet penetration. For instance

• As per the Global System for Mobile Communications Association (GSMA), in 2023, about 4.3 billion people, which is 54% of the global population, owned a smartphone.

The higher internet penetration & smartphone accessibility have led to a shift towards online e-commerce platforms. These platforms provide convenience to consumers by offering them the option to make payments online. Also, these platforms deliver pharmaceutical products at home. The flexibility & convenience offered by these online platforms has made them a popular choice among inhabitants, enhancing their market share.

Furthermore, the increasing number of online pharmacies is propelling segmental market growth. For instance,

• In 2024 Amazon launched same-day prescription delivery in New York and Los Angeles. Similarly, in 2023, MrMed, an online pharmacy launched a mobile app for access to affordable super-specialty medicines in India.

As online pharmacies continue to innovate and expand their services across the world, access to essential medications, including those meant for exocrine pancreatic insufficiency would increase, driving the segmental market growth.

Global Exocrine Pancreatic Insufficiency Market (2024-30): Regional Projection

Geographically, the Global Exocrine Pancreatic Insufficiency Market expands across:

• North America
• South America
• Europe
• The Middle East & Rest of Africa
• Asia-Pacific

Geographically, North America holds a noteworthy share in the Global Exocrine Pancreatic Insufficiency Market. North American nations have a higher rate of obese & diabetic populations, which are more susceptible to getting pancreatic disorders. Therefore, there is a higher need for Exocrine Pancreatic Insufficiency therapies in North America. Further, the hospitals in the countries within the region are upgrading their infrastructure, owing to which they are adopting different modern technologies, consequently uplifting market growth.

Additionally, non-government organizations are increasingly conducting health awareness programs in the region. Owing to this, more individuals are becoming aware of the diseases and related therapies. This helps the consumers to detect the illness at an earlier stage and receive the treatment accordingly. Therefore, there is a notable surge in the demand for both nutritional & PERT therapies in North America.

Global Exocrine Pancreatic Insufficiency Industry Recent Development:

• 2023:  Nestlé, in partnership with enzyme engineering company Codexis, Inc., announced preliminary results from their Phase 1 study to address the limitations of current pancreatic enzyme replacement therapies (PERT).

Gain a Competitive Edge with Our Global Exocrine Pancreatic Insufficiency Market Report

• The Global Exocrine Pancreatic Insufficiency Market Report by Markntel Advisors provides a detailed & thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
• This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
• The Global Exocrine Pancreatic Insufficiency Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.